Eagle Asset Management Inc. Has $11.12 Million Stake in Glaukos Co. (NYSE:GKOS)

Eagle Asset Management Inc. trimmed its holdings in shares of Glaukos Co. (NYSE:GKOS) by 12.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,455 shares of the medical instruments supplier’s stock after selling 10,978 shares during the period. Eagle Asset Management Inc. owned 0.14% of Glaukos worth $11,121,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Point72 Asset Management L.P. acquired a new position in shares of Glaukos in the 2nd quarter valued at $67,460,000. Primecap Management Co. CA lifted its stake in Glaukos by 43.9% in the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock valued at $144,483,000 after buying an additional 372,180 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in Glaukos by 148.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock valued at $48,805,000 after buying an additional 246,322 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Glaukos by 47.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock worth $83,609,000 after buying an additional 207,338 shares during the period. Finally, Iron Triangle Partners LP increased its stake in shares of Glaukos by 75.6% in the 1st quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock valued at $40,500,000 after acquiring an additional 184,919 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Needham & Company LLC increased their target price on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Wells Fargo & Company lifted their price objective on shares of Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Stifel Nicolaus lifted their target price on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $134.55.

Insider Activity

In other news, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. This trade represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Stock Up 2.3 %

Shares of NYSE GKOS opened at $144.00 on Friday. The stock has a market capitalization of $7.94 billion, a P/E ratio of -47.68 and a beta of 1.02. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 52 week low of $59.22 and a 52 week high of $146.09. The stock’s fifty day moving average is $132.40 and its 200 day moving average is $123.58.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. During the same quarter last year, the business posted ($0.50) EPS. The firm’s revenue for the quarter was up 23.9% on a year-over-year basis. Sell-side analysts forecast that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.